Can a contrast ultrasound predict radiation success in sarcoma?

NCT ID NCT07436364

Recruiting now Knowledge-focused Sponsor: Thomas Jefferson University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This small pilot study is testing whether contrast-enhanced ultrasound (CEUS) can help doctors monitor how soft tissue sarcoma responds to radiation therapy. Ten adults scheduled for radiation will get CEUS scans before, during, and after treatment. The goal is to see if CEUS images can be combined with CT or MRI scans to better predict tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Definity (contrast agent for ultrasound)
What this could lead to: If successful, this could lead to a non-invasive way to see how well radiotherapy is working for soft tissue sarcoma, potentially guiding more personalized treatment.
What could go wrong: This is a very small, early-phase pilot study with only 10 participants, so results may not apply broadly. The technique may not prove reliable enough for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOFT TISSUE SARCOMA

Contacts and locations

Locations

Thomas Jefferson University Hospital
RECRUITING

Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.